Small Intestine News and Research

RSS

Scientists discover hormone pathway that can lead to new diabetes treatment

Researchers at UT Southwestern Medical Center have discovered a hormone pathway that potentially could lead to new ways of treating type 1 diabetes independent of insulin, long thought to be the sole regulator of carbohydrates in the liver.

25 Mar 2011

UCSF collaborates with Zcube to develop new ways to deliver drugs

A pill filled with microscopic, drug-laden adhesive squares is at the center of an agreement between UCSF and Zcube srl, the research corporate venture arm of Italian pharmaceutical leader Zambon Co., SpA, to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.

28 Feb 2011

Study: Gastric bypass surgery may lead to better health outcomes in patients with diabetes

Gastric bypass surgery appears to lead to better long-term results including greater weight loss, resolution of diabetes and improved quality of life compared with sleeve gastrectomy and "lap-band" surgery, according to two reports in the February issue of Archives of Surgery, one of the JAMA/Archives journals.

22 Feb 2011

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

For 60 years, scientists have puzzled over the possibility of a hepatic osmoreceptor that influences blood pressure regulation. Now, researchers of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, the Experimental and Clinical Research Center of the MDC and Charit- and the Hannover Medical School appear to have made a breakthrough discovery.

27 Jan 2011

Magnetic maneuverable capsule safe and well-tolerated in the stomach

A study from researchers in Germany showed that magnetic maneuvering of a modified capsule endoscope in the stomach of healthy volunteers under clinical conditions is safe, well-tolerated, and technically feasible. Maneuverability of the capsule within the stomach was excellent and visualization of the gastric mucosa, the inner lining of the stomach, was satisfactory in the majority of subjects.

19 Jan 2011

New findings show reduced vitamin D absorption in patients with quiescent CD

Researchers from Boston University School of Medicine have for the first time shown that reduced vitamin D absorption in patients with quiescent Crohn's disease may be the cause for their increased risk for vitamin D deficiency.

19 Jan 2011

Health Canada approves GORE VIABIL Biliary Endoprosthesis device

W. L. Gore & Associates, Inc. today announced it has received approval from Health Canada for the Removable GORE VIABIL Biliary Endoprosthesis.

17 Jan 2011

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS Pharmaceuticals, Inc. a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced the completion of the 24-week treatment phase of the company's Phase 3 registration study of GATTEX® (teduglutide).

11 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

Tap water cancer chemical detected

A new analysis has revealed a potential carcinogen in the tap water of 31 U.S. cities and experts are looking for ways to reduce exposure of the communities. The chemical called hexavalent chromium, got public attention in the 2000 film “Erin Brockovich” and has been found to cause cancer in laboratory animals by the National Toxicology Program, part of the National Institutes of Health.

21 Dec 2010

Gastric bypass surgeries performed using da Vinci Surgical System

Friday, bariatric surgeons at St. Vincent's East, Lee Schmitt, M.D., F.A.C.S. and Robert (Les) Miles, M.D., F.A.C.S., of Alabama Weight Loss Surgery, performed two gastric bypass surgeries using the da Vinci® Surgical System, also known as the "robot." Dr. Schmitt and Dr. Miles will be the only bariatric surgeons in the state of Alabama routinely offering patients this minimally invasive option in gastric bypass surgery.

21 Dec 2010

Tips to enjoy holiday food and other special parts of the season

While most of us look forward with anticipation to the culinary delights of the holiday season, the decedent buffet can be treacherous territory for those with food-related health concerns.

17 Dec 2010

New study says celiac disease patients should go on gluten-free diet

Findings from a new study of 141 adults add to an ongoing medical debate over which patients with symptoms of celiac disease should go on a gluten-free diet. Published in ACS' Journal of Proteome Research, the study concludes that people currently diagnosed as "potential" celiac disease patients and not advised to follow a gluten-free diet may not be "potential" patients at all. Rather, the scientists found that these patients have the same distinctive metabolic fingerprint as patients with full-blown disease who do benefit from gluten-free diets.

16 Dec 2010

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Scientists at the University of California, San Diego School of Medicine have described for the first time a key inhibitory role for the IL-1 signaling pathway in the human innate immune system, providing novel insights into human inflammatory bowel disease (IBD) and potential new treatments.

15 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

EFSA publishes positive opinion on disease risk reduction health claim for oat beta-glucan

A scientific panel of the European Food Safety Authority (EFSA) published its positive opinion on a disease risk reduction health claim dossier for oat beta-glucan on 8. December 2010, following an application from CreaNutrition AG submitted pursuant to Article 14 of the EC regulation on nutrition and health claims.

9 Dec 2010

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

The management of children with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis has evolved significantly over the past decade. With a surge of pediatric research in the field, quality of life has become an important focus of study, as indicated by the number of related abstracts that will be presented at the 2010 Advances in Inflammatory Bowel Diseases, the Crohn's & Colitis Foundation's Clinical & Research Conference beginning tomorrow in Hollywood, Florida.

9 Dec 2010

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

ACE-041 drug may provide new option to treat cancer

Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.

19 Nov 2010

Small Intestine News and Research

Scientists discover hormone pathway that can lead to new diabetes treatment

UCSF collaborates with Zcube to develop new ways to deliver drugs

Study: Gastric bypass surgery may lead to better health outcomes in patients with diabetes

Researchers discover new sensory neurons that mediate BP and metabolism regulation in liver

Magnetic maneuverable capsule safe and well-tolerated in the stomach

New findings show reduced vitamin D absorption in patients with quiescent CD

Health Canada approves GORE VIABIL Biliary Endoprosthesis device

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

Tap water cancer chemical detected

Gastric bypass surgeries performed using da Vinci Surgical System

Tips to enjoy holiday food and other special parts of the season

New study says celiac disease patients should go on gluten-free diet

Key inhibitory role for IL-1 signaling pathway in human innate immune system

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

EFSA publishes positive opinion on disease risk reduction health claim for oat beta-glucan

Researchers to address HRQOL issues for pediatric patients with IBD at annual conference

Immunity-enhancing probiotics may be the best line of defense for good health

ACE-041 drug may provide new option to treat cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News